Literature DB >> 11515885

Reversal of preexisting vasospasm in coronary artery conduits.

J Chanda1, C C Canver.   

Abstract

BACKGROUND: To reverse preexisting coronary graft spasm, we investigated the vasodilative effect of the average therapeutic plasma concentration of nitroglycerin (NTG) alone and various calcium antagonists in combination with NTG in human arterial and venous conduits.
METHODS: Vasodilative effects of 2 x 10(-8) mol/L NTG alone and 10(-8) mol/L NTG in combination with 2.2 x 10(-7) mol/L diltiazem, 2.8 x 10(-7) mol/L nifedipine, 10(-7) mol/L verapamil, or 5.6 x 10(-8) mol/L nicardipine were assessed in human radial artery, internal thoracic artery, and saphenous vein segments precontracted with a mixture of ten times the maximum plasma concentrations of endothelin-1 (8.6 x 10(-13) mol/L), angiotensin II (36 x 10(-11) mol/L), 5-hydroxytryptamine (3.4 x 10(-7) mol/L), and norepinephrine (1.7 x 10(-8) mol/L). The studies were done in organ baths.
RESULTS: The therapeutic concentration of NTG alone or nifedipine, verapamil, diltiazem, or nicardipine in combination with NTG caused equal relaxation in a particular group of vascular segments (average vasodilation: radial artery, 83% to 95% [p = 0.7608 by analysis of variancel; saphenous vein, 47% to 70% [p = 0.3142]; internal thoracic artery, 54% to 79% [p = 0.27831). These combinations were not equally effective when compared between different groups of vascular segments (vasodilation; radial artery > internal thoracic artery > saphenous vein [p < 0.0001 by analysis of variance]). Although not significant, in comparison with NTG alone, NTG in combination with a calcium antagonist caused less vasodilation in any group of vascular segments.
CONCLUSIONS: Nitroglycerin alone or in combination with nifedipine, verapamil, diltiazem, or nicardipine effectively reverses preexisting vasospasm in coronary artery conduits.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11515885     DOI: 10.1016/s0003-4975(01)02799-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

Review 1.  Coronary revascularization in the 21st century. Emphasis on contributions by Japanese surgeons.

Authors:  Hendrick B Barner
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-12

2.  A functional and histopathological comparison of proximal and distal saphenous vein contractility and morphology.

Authors:  Ilhan Golbasi; Arda Tasatargil; Nazif Hikmet Aksoy; Gulay Sadan; Edibe Karasu; Cengiz Turkay; Omer Bayezid
Journal:  Tex Heart Inst J       Date:  2005

Review 3.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

4.  Norepinephrine for hypotensive vasodilatation after cardiac surgery: impact on renal function.

Authors:  Hiroshi Morimatsu; Shigehiko Uchino; John Chung; Rinaldo Bellomo; Jai Raman; Brian Buxton
Journal:  Intensive Care Med       Date:  2003-05-22       Impact factor: 17.440

5.  Angiotensin II, as well as 5-hydroxytriptamine, is a potent vasospasm inducer of saphenous vein graft for coronary artery bypass grafting in patients with diabetes mellitus.

Authors:  Atsuko Yokota; Shuji Gamoh; Naoko Tanaka-Totoribe; Tatsuo Shiba; Masachika Kuwabara; Eisaku Nakamura; Takahiro Hayase; Hiroaki Hisa; Kunihide Nakamura; Ryuichi Yamamoto
Journal:  Biochem Biophys Rep       Date:  2016-03-17

6.  The radial artery as a coronary bypass conduit: dealing with hypereactivity.

Authors:  Suleiman Kharabsheh; Zohair Al-Halees
Journal:  Ann Saudi Med       Date:  2005 Jan-Feb       Impact factor: 1.526

7.  Perioperative diltiazem or nitroglycerin in on-pump coronary artery bypass: A systematic review and network meta-analysis.

Authors:  Yirui Hu; Xinbei Yang; Li Zhang; Xianren Wu; Anastasia Yian Liu; Joseph A Boscarino; H Lester Kirchner; Alfred S Casale; Xiaopeng Zhang
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.